Role of aldosterone and angiotensin II in insulin resistance: An update

Clinical Endocrinology

Volumn 71, Issue 1, 2009, Pages 1-6

  Lastra Lastra, Guido ^b   Sowers, James R ^c   Restrepo Erazo, Katherine ^b   Manrique Acevedo, Camila ^c   Lastra González, Guido ^a,c  

^a D109 HSC Diabetes Center   (United States)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^c University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; INSULIN; MINERALOCORTICOID; REACTIVE OXYGEN METABOLITE;

CARDIOVASCULAR DISEASE; ENDOTHELIAL DYSFUNCTION; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER; MORBIDITY; MORTALITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SKELETAL MUSCLE;

ALDOSTERONE; ANGIOTENSIN II; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; INSULIN RESISTANCE; METABOLIC DISEASES; RENIN-ANGIOTENSIN SYSTEM;

EID: 66949144688     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03498.x     Document Type: Review

References (48)

1. Lastra, G., Manrique, C., McFarlane, S.I. et al. (2006) Cardiometabolic syndrome and chronic kidney disease. Current Diabetes Reports, 6, 207 212. (Pubitemid 43918646)
2. Modan, M., Halkin, H., Almog, S. et al. (1985) Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. Journal of Clinical Investigation, 75, 809 817. (Pubitemid 15111002)
3. Despres, J.P., Lamarche, B., Mauriege, P. et al. (1996) Hyperinsulinemia as an independent risk factor for ischemic heart disease. New England Journal of Medicine, 334, 952 958.
4. Pitt, B., Remme, W., Zannad, F. et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine, 348, 1309 1321. (Pubitemid 36384098)
5. Brilla, C.G. Weber, K.T. (1992) Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. Journal of Laboratory and Clinical Medicine, 120, 893 901. (Pubitemid 23002899)
6. Giacchetti, G., Sechi, L.A., Rilli, S. et al. (2005) The rennin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends in Endocrinology and Metabolism, 16, 120 126. (Pubitemid 40432462)
7. Report of the Expert Committee on the Diagnosis Classification of Diabetes Mellitus (2002) Diabetes Care, 25, S5 S20.
8. Henquin, J.C. (2000) Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes, 49, 1751 1760.
9. Zillich, A.J., Garg, J., Basu, S. et al. (2006) Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension, 48, 219 224. (Pubitemid 44309815)
10. Fallo, F., la Mea, P., Sonino, N. et al. (2007) Adiponectin and insulin sensitivity in primary aldosteronism. American Journal of Hypertension, 20, 855 861. (Pubitemid 47176347)
11. Shimamoto, K., Shiiki, M., Ise, T. et al. (1994) Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism? Journal of Human Hypertension, 8, 755 759. (Pubitemid 24319387)
12. Sindelka, G., Widimsky, J., Haas, T. et al. (2000) Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment. Experimental and Clinical Endocrinology and Diabetes, 108, 21 25. (Pubitemid 30160431)
13. Petrasek, D., Jensen, G., Tuck, M. et al. (1992) In vitro effects of insulin on aldosterone production in rat zona glomerulosa cells. Life Sciences, 50, 1781 1787.
14. Laverty, G., Bjarnadottir, S., Elbrond, V.S. et al. (2001) Aldosterone suppresses expression of an avian colonic sodium-glucose cotransporter. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 281, R1041 R1050.
15. Campion, J., Maestro, B., Mata, F. et al. (1999) Inhibition by aldosterone of insulin receptor mRNA levels and insulin binding in U-937 human promonocytic cells. Journal of Steroid Biochemistry and Molecular Biology, 70, 211 218. (Pubitemid 29528432)
16. Catena, C., Lapenna, R., Baroselli, S. et al. (2006) Insulin sensitivity in patients with primary aldosteronism: a follow-up study. Journal of Clinical Endocrinology and Metabolism, 91, 3457 3463. (Pubitemid 44402119)
17. Shamiss, A., Carroll, J. Rosenthal, T. (1992) Insulin resistance in secondary hypertension. American Journal of Hypertension, 5, 26 28.
18. Fallo, F., Veglio, F., Bertello, C. et al. (2006) Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. Journal of Clinical Endocrinology and Metabolism, 91, 454 459. (Pubitemid 43236909)
19. Rossi, G.P., Belfiore, A., Bernini, G. et al. (2008) Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. Journal of Clinical Endocrinology and Metabolism, 93, 2566 2571. (Pubitemid 352008521)
20. Jeon, J.H., Kim, K.Y., Kim, J.H. et al. (2008) A novel adipokine CTRP1 stimulates aldosterone production. FASEB Journal, 22, 1502 1511.
21. Caprio, M., Feve, B., Claes, A. et al. (2007) Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB Journal, 21, 2185 2194. (Pubitemid 47026453)
22. Christ, M., Sippel, K., Eisen, C. et al. (1994) Non-classical receptors for aldosterone in plasma membranes from pig kidneys. Molecular and Cellular Endocrinology, 99, R31 R34.
23. Wehling, M., Kasmayr, J. Theisen, K. (1991) Rapid effects of mineralocorticoids on sodium-proton exchanger: genomic or nongenomic pathway? American Journal of Physiology. Endocrinology and Metabolism, 260, E719 E726.
24. Fujii, Y., Takemoto, F. Katz, A.I. (1990) Early effects of aldosterone on Na-K pump in rat cortical collecting tubules. American Journal of Physiology. Renal Physiology, 259, F40 F45.
25. Harvey, B.J., Doolan, C.M., Condliffe, S.B. et al. (2002) Non-genomic convergent and divergent signalling of rapid responses to aldosterone and estradiol in mammalian colon. Steroids, 67, 483 491. (Pubitemid 34311764)
26. Callera, G.E., Touyz, R.M., Tostes, R.C. et al. (2005) Aldosterone activates vascular p38MAP Kinase and NADPH oxidase Via C-Src. Hypertension, 45, 773 779. (Pubitemid 40418380)
27. Ohtsu, H., Suzuki, H., Nakashima, H. et al. (2006) Angiotensin II signal transduction through small GTP-binding proteins. Mechanism and Significance in Vascular Smooth Muscle Cells Hypertension, 48, 534 540.
28. Rossi, G., Boscaro, M., Ronconi, V. et al. (2005) Aldosterone as a cardiovascular risk factor. Trends in Endocrinology and Metabolism, 16, 104 107. (Pubitemid 40432459)
29. Hitomi, H., Kiyomoto, H., Nishiyama, A. et al. (2007) Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension, 50, 750 755. (Pubitemid 47442741)
30. Taniyama, Y., Hitomi, H., Shah, A. et al. (2005) Mechanisms of reactive oxygen species-dependent downregulation of Insulin receptor Substrate-1 by Angiotensin, II. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 1142 1147. (Pubitemid 40776600)
31. Gillespie, E.L., White, C.M., Kardas, M. et al. (2005) The Impact of ACE Inhibitors or angiotensin II Type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care, 28, 2261 2266. (Pubitemid 41242483)
32. Scheen, A.J. (2004) Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes and Metabolism, 30, 487 496. (Pubitemid 40070350)
33. American Diabetes Association (2008) Standards of medical care in diabetes-2008. Diabetes Care, 31 (Suppl. 1 S12 S54.
34. The DREAM Trial Investigators (2006) Effect of ramipril on the incidence of diabetes. New England Journal of Medicine, 355, 1551 1562.
35. Vijayaraghavan, K. Deedwania, P.C. (2005) The renin angiotensin system as a therapeutic target to prevent diabetes and its complications. Cardiology Clinics, 23, 165 183. (Pubitemid 40203092)
36. Pitt, B., Zannad, F., Remme, W.J. et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New England Journal of Medicine, 341, 709 717. (Pubitemid 29407370)
37. Lastra, G., Whaley-Connell, A., Manrique, C. et al. (2008) Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. American Journal of Physiology. Endocrinology and Metabolism, 295, E110 E116.
38. Davies, J.I., Band, M., Morris, A. et al. (2004) Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia, 47, 1687 1694. (Pubitemid 40022402)
39. Swaminathan, K., Davies, J., George, J. et al. (2008) Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia, 51, 762 768.
40. Matsumoto, S., Takebayashi, K. Aso, Y. (2006) The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism, 55, 1645 1652. (Pubitemid 44827131)
41. Wei, Y., Sowers, J.R., Nistala, R. et al. (2006) Angiotensin II-induced NADPH oxidase activation Impairs insulin signaling in skeletal muscle cells. Journal of Biological Chemistry, 281, 35137 35146. (Pubitemid 46036553)
42. Richey, J.M., Ader, M., Moore, D. et al. (1999) Angiotensin II induces insulin resistance independent of changes in interstitial insulin. American Journal of Physiology. Endocrinology and Metabolism, 277, E920 E926.
43. Qi, D. Rodrigues, B. (2007) Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism. American Journal of Physiology. Endocrinology and Metabolism, 292, E654 E667.
44. Dimitriadis, G., Leighton, B., Parry-Billings, M. et al. (1997) Effects of glucocorticoid excess on the sensitivity of glucose transport and metabolism to insulin in rat skeletal muscle. Biochemical Journal, 321, 707 712. (Pubitemid 27084879)
45. Ruzzin, J., Wagman, A.S. Jensen, J. (2005) Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. Diabetologia, 48, 2119 2130. (Pubitemid 41416925)
46. Giorgino, F., Almahfouz, A., Goodyear, L.J. et al. (1993) Glucocorticoid regulation of insulin receptor and substrate IRS-1 tyrosine phosphorylation in rat skeletal muscle in vivo. Journal of Clinical Investigation, 91, 2020 2030. (Pubitemid 23141474)
47. Jacobson, P.B., von Geldern, T.W., Ohman, L. et al. (2005) Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes. Journal of Pharmacology and Experimental Therapeutics, 314, 191 200. (Pubitemid 41058255)
48. Chen, J., Muntner, P., Hamm, L.L. et al. (2003) Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. Journal of the American Society of Nephrology, 14, 469 477. (Pubitemid 36150872)